ライフサイエンスコーパス: first-line therapy

1 evel of efficacy required for their use as a first line therapy.

2 determine whether these drugs have a role in first line therapy.

3 atment and after 3, 6, and 9 days of empiric first-line therapy.

4 ed, but available data support penicillin as first-line therapy.

5 high-quality evidence supports its use as a first-line therapy.

6 n was time-to-treatment failure (TTF) of the first-line therapy.

7 able relapses identified by slow response to first-line therapy.

8 ts a stepwise approach with acetaminophen as first-line therapy.

9 s in CLL patients receiving current-standard first-line therapy.

10 therapy are challenging its current role as first-line therapy.

11 ed into question the use of glycopeptides as first-line therapy.

12 acy and safety of pazopanib and sunitinib as first-line therapy.

13 han half of patients are cured with standard first-line therapy.

14 th high genetic barrier to resistance as the first-line therapy.

15 glabrata and echinocandins are often used as first-line therapy.

16 ed to the proteasome inhibitor bortezomib, a first-line therapy.

17 further erodes the position of vancomycin as first-line therapy.

18 t candidates received standard site-specific first-line therapy.

19 Outcome was not affected by the choice of first-line therapy.

20 allo-SCT in all myeloma patients as part of first-line therapy.

21 re and 3 and/or 6 months after initiation of first-line therapy.

22 inimal residual disease level achieved after first-line therapy.

23 ul in approximately 60% of cases that failed first-line therapy.

24 ance, which makes alpha-agonists the logical first-line therapy.

25 genetic barrier to resistance are considered first-line therapy.

26 ercent of patients received bevacizumab with first-line therapy.

27 EGFR TKI or chemotherapy is the appropriate first-line therapy.

28 ternative therapy (switch maintenance) after first-line therapy.

29 h advanced NSCLC after progression following first-line therapy.

30 disease progressing more than 6 months after first-line therapy.

31 causes more then 50% mortality rate despite first-line therapy.

32 ieved at least stable disease after standard first-line therapy.

33 ses a mortality rate of at least 50% despite first-line therapy.

34 al expertise, either option is acceptable as first-line therapy.

35 ocumented clinical progression subsequent to first-line therapy.

36 are cancers that have limited data regarding first-line therapy.

37 ancer will develop progressive disease after first-line therapy.

38 well-recognized and compromises response to first-line therapy.

39 est treated with combination chemotherapy as first-line therapy.

40 determine whether these drugs have a role in first-line therapy.

41 mplete or partial response was achieved with first-line therapy.

42 ndoscopic balloon dilation and should be the first-line therapy.

43 apy is routinely considered at relapse after first-line therapy.

44 atitis, and cyclosporine may be effective as first-line therapy.

45 nitinib and temsirolimus versus cytokines in first-line therapy.

46 herapy and reduction in immunosuppression as first-line therapy.

47 he use of raltegravir 1200 mg once daily for first-line therapy.

48 patients achieved a complete response after first-line therapy.

49 acy rate (<80%) and should not be adopted as first-line therapy.

50 of HIV-infected patients receiving DTG-based first-line therapy.

51 ertuzumab, which is now included as standard first-line therapy.

52 astric cancer and progressed during or after first-line therapy.

53 ggests caution in prescribing rituximab as a first-line therapy.

54 th a higher rate of early death when used as first-line therapy.

55 use of rituximab both as second-line and as first-line therapy.

56 uring or within 6 months of the last dose of first-line therapy.

57 r vemurafenib (960 mg twice daily) orally as first-line therapy.

58 b monotherapy (960 mg twice-daily) orally as first-line therapy.

59 e evaluated lenalidomide plus rituximab as a first-line therapy.

60 ies were included in analysis of efficacy of first-line therapies.

61 -proxetil) are not as effective as empirical first-line therapies.

62 lter P. falciparum susceptibility to current first-line therapies.

63 for inclusion in the analysis of efficacy of first-line therapies.

64 ght sensitize ovarian tumors to conventional first-line therapies.

65 ity in at least 50% of cases despite current first-line therapies.

66 nefits and harms compared with each other as first-line therapy?

67 49 (42%) of 116 patients failed first-line therapy, 2-year survival was 88% (95% CI 81-9

68 Among 82 patients evaluable for response to first-line therapy, 31 patients received neoadjuvant che

69 plantation (allo-SCT) for myeloma as part of first-line therapy, a donor versus no-donor analysis was

70 The clinical benefits of using multiple first-line therapies against malaria suggest that MFT po

71 of trials to test these agents as potential first-line therapies and has provided a fascinating wind

72 for patients with DLE that is refractory to first-line therapies and who risk late-stage disease wit

73 e a strong recommendation for hydroxyurea as first-line therapy and a weak recommendation for chronic

74 c drug therapy is generally recommended as a first-line therapy and drug selection is on the basis of

75 s are lacking benzodiazepines are considered first-line therapy and N-Methyl-d-aspartate receptor ant

76 ntify which patients should receive standard first-line therapy and which should receive a protease-i

77 immunotherapy 2-5 months after completion of first-line therapy and who were assessed as having a hig

78 s alone, radioiodine is increasingly used as first line therapy, and is the preferred choice for rela

79 8% of those on treatment were on recommended first-line therapies, and 30% were on lamivudine monothe

80 by geographic region, time to progression on first-line therapy, and disease measurability, was used.

81 erapy regimens have been well established as first-line therapy, and have been shown to increase surv

82 g to the presence of metastases, duration of first-line therapy, and Karnofsky performance status.

83 stant disease progressing within 6 months of first-line therapy, and randomised trials might be appro

84 es; (2) second-line LA-ART for those failing first-line therapy; and (3) first-line LA-ART for ART-na

85 Treatment after failure of those first-line therapies are disappointing overall, with man

86 avenous immunoglobulin or corticosteroids as first-line therapy at other gestational periods.

87 nsensus sequences from patients treated with first-line therapies between 1989 and 2013 to confirm th

88 Oral iron is usually recommended as first-line therapy, but the most recent intravenous iron

89 Adopting either as a first-line therapy carries major cost and resource impli

90 As a first-line therapy, combined Endo and Epi VT ablation in

91 rtion of complete hematologic response after first-line therapy compared to patients with a dFLC leve

92 clear-cell carcinoma who progressed despite first-line therapy containing sunitinib, bevacizumab plu

93 PI-based first-line therapy could be reconsidered when antiretrov

94 e addition of evofosfamide to doxorubicin as first-line therapy did not improve overall survival comp

95 , documented complete or partial response to first-line therapy, Eastern Cooperative Oncology Group p

96 delines recommend a maximum of six cycles of first-line therapy, even in responding patients, recent

97 t option in NMO patients who do not tolerate first-line therapy, experience ongoing relapses or in si

98 ardiopulmonary bypass should be available if first-line therapies fail to secure an injured airway.

99 rove the infection treatment efficacy.If the first-line therapy fails a second-line treatment using t

100 scriptase inhibitors (NRTIs) are employed in first line therapies for the treatment of human immunode

101 hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML).

102 promote non-pharmacological interventions as first line therapy for depression and anxiety in people

103 agent, MitoQ, alone and in combination with first line therapy for DKD.

104 st that surgical resection should remain the first line therapy for patients with HCC and compensated

105 l therapy that demonstrated superiority to 2 first-line therapies for AR.

106 Glucocorticoids (GCs) are used as first-line therapies for generalized suppression of infl

107 First-line therapies for HIT are argatroban or lepirudin

108 rspective of co-targeting NO metabolism with first-line therapies for improved outcome.

109 ment (TME) hampers the long-term efficacy of first-line therapies for lung cancer.

110 Traditional beta2-agonists are seen as first-line therapies for moderate bronchiolitis and asth

111 Vancomycin and metronidazole are first-line therapies for most patients, although treatme

112 l (3 g in a single dose) are all appropriate first-line therapies for uncomplicated cystitis.

113 Cisplatin is a cytotoxic drug used as a first-line therapy for a wide variety of cancers.

114 make this a reasonable option to consider as first-line therapy for achalasia.

115 and development, prevention of osteoporosis, first-line therapy for active disease, and maintenance o

116 The first-line therapy for acute TTP is based on daily thera

117 ifestyle modification, metformin remains the first-line therapy for adolescents with type 2 diabetes,

118 oad spectrum kinase inhibitor sunitinib is a first-line therapy for advanced clear cell renal cell ca

119 stage IIIB-IV KRAS-mutant NSCLC; had failed first-line therapy for advanced NSCLC; had WHO performan

120 fit of adding evofosfamide to doxorubicin as first-line therapy for advanced soft-tissue sarcomas.

121 evidence to recommend combination therapy as first-line therapy for all patients with chronic hepatit

122 l-asparaginase (ASNase) is a first-line therapy for ALL that breaks down asparagine a

123 l experience with proteasome inhibition as a first-line therapy for AMR is presented.

124 n thiazides and thiazide-like diuretics as a first-line therapy for any outcome.

125 Lithium is a first-line therapy for bipolar affective disorder.

126 Lithium is the first-line therapy for bipolar disorder.

127 Fluconazole (FLC) remains a first-line therapy for candidemia; and voriconazole (VRC

128 Statins are first-line therapy for cardiovascular disease prevention

129 Although IM is now established as first-line therapy for chronic phase chronic myeloid leu

130 ion with topical corticosteroid therapy as a first-line therapy for chronic sinusitis.

131 CLL8) that included 1372 patients receiving first-line therapy for CLL.

132 emoimmunotherapy (CIT) has been the standard first-line therapy for CLL.

133 R,R-1,2-diaminocyclohexane), an FDA-approved first-line therapy for colorectal cancer.

134 Present first-line therapy for diffuse large B-cell lymphoma, a

135 To assess a short course of cyclosporine as first-line therapy for DIHS.

136 While benzodiazepines are a first-line therapy for Dravet syndrome, they are limited

137 Guidelines recommend statins as first-line therapy for dyslipidemia.

138 th nifurtimox, is being used increasingly as first-line therapy for gambiense disease.

139 omycin-based regimens are commonly used as a first-line therapy for Helicobacter pylori-positive pati

140 CONCLUSION HTX is an effective and feasible first-line therapy for HER2-positive locally advanced or

141 cizumab (7.5 and 15 mg/kg) with docetaxel as first-line therapy for human epidermal growth factor rec

142 olled trials that evaluated beta-blockers as first-line therapy for hypertension with follow-up for a

143 mized controlled trials that evaluated BB as first-line therapy for hypertension with follow-up for a

144 Zanamivir should be considered as first-line therapy for influenza in patients with lympho

145 TIP demonstrated efficacy as first-line therapy for intermediate- and poor-risk GCTs

146 ncreased PFS when combined with docetaxel as first-line therapy for MBC compared with docetaxel plus

147 in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRY

148 in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRY

149 Vancomycin is the first-line therapy for methicillin-resistant Staphylococ

150 Oral and rectal 5-ASA are recommended first-line therapy for mild to moderate UC, with cortico

151 shock wave lithotripsy (SWL), a noninvasive first-line therapy for millions of nephrolithiasis patie

152 ' national policies recommend using a single first-line therapy for most clinical malaria cases.

153 Although corticosteroids remain the first-line therapy for most forms of HESs, the availabil

154 Nafcillin and cefazolin are considered first-line therapy for most infections with methicillin-

155 mide (Revlimid), and dexamethasone (BiRD) as first-line therapy for multiple myeloma.

156 costeroids (CSs) and cyclosporine A (CsA) as first-line therapy for newly diagnosed cGVHD after allo-

157 h lifestyle interventions are considered the first-line therapy for nonalcoholic fatty liver disease

158 of combination nivolumab plus ipilimumab as first-line therapy for NSCLC.

159 with macrolides, including azithromycin, as first-line therapy for patients hospitalized with pneumo

160 e per week to paclitaxel with bevacizumab as first-line therapy for patients with advanced breast can

161 y and safety of nilotinib versus imatinib as first-line therapy for patients with advanced GISTs.

162 e only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocell

163 agulation) should be routinely considered as first-line therapy for patients with extensive acute ili

164 The first-line therapy for patients with keratitis is differ

165 dermal growth factor receptor (EGFR) are the first-line therapy for patients with metastatic colorect

166 r superior to paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-n

167 using doxycycline appears to be a reasonable first-line therapy for patients with OAML.

168 Androgen deprivation therapy (ADT) is first-line therapy for patients with prostate cancer (PC

169 with bleomycin in general or specifically as first-line therapy for patients with treatment naive, ad

170 Benzodiazepines are considered first-line therapy for pediatric status epilepticus.

171 to be approved for clinical use, and remains first-line therapy for Philadelphia chromosome (Ph+)-pos

172 trimethoprim-sulfamethoxazole is considered first-line therapy for Pneumocystis pneumonia prevention

173 deprivation is currently a standard-of-care, first-line therapy for prostate cancer in the United Sta

174 tanercept or methotrexate; the latter is the first-line therapy for RA.

175 -positive patients who received tamoxifen as first-line therapy for recurrent or metastatic disease,

176 IFN-beta has been used as a first-line therapy for relapsing-remitting multiple scle

177 ectives with initial anticoagulation, and as first-line therapy for selected patients with acute ilio

178 Parenteral artesunate is recommended as first-line therapy for severe malaria.

179 angiotensin-converting enzyme inhibitors as first-line therapy for SRC, and give recommendations for

180 Anakinra as first-line therapy for systemic JIA was associated with

181 ib 100 mg once daily as a safe and effective first-line therapy for the long-term treatment of CML-CP

182 elective beta-blocker propranolol has become first-line therapy for the treatment of complicated infa

183 Although opioids remain a first-line therapy for the treatment of severe chronic p

184 h surgical controls and should be considered first-line therapy for this disease.

185 the addition of ipatasertib to paclitaxel as first-line therapy for triple-negative breast cancer.

186 The evidence supports metformin as first-line therapy for type 2 diabetes, given its relati

187 Metformin, a first-line therapy for type 2 diabetes, is the only drug

188 doxine-pyrimethamine has been widely used as first-line therapy for uncomplicated malaria throughout

189 mbolization (TACE) is currently considered a first-line therapy for unresectable HCC.

190 Topical corticosteroids are the current first-line therapy for vulvar lichen sclerosus (VLS).

191 itaxel is an active and tolerable regimen as first-line therapy for women with MBC.

192 (SABA) delivered by metered-dose inhaler as first-line therapy for younger and older children (hospi

193 Participants aged 18 years or older for whom first-line therapy had failed, with HIV RNA concentratio

194 ne therapy in HIV-infected patients for whom first-line therapy had failed.

195 oaches with the use of more potent agents as first-line therapy has been proposed, but they are still

196 IV drug resistance among individuals in whom first-line therapy has failed and clinical and resistanc

197 ns, and outline options for patients in whom first-line therapy has failed.

198 Balloon angioplasty, the first-line therapy, has a tendency to lead to subsequent

199 Gains from first-line therapies have been modest but consistent; ho

200 ell lung cancer (NSCLC) who progress through first-line therapy have poor progression-free survival (

201 tis (SAR) and to compare its efficacy with 2 first-line therapies (ie, intranasal azelastine and intr

202 Currently, imatinib is considered first line therapy in all patients with early chronic ph

203 Finally, the safety and efficacy of standard first-line therapies in paediatric multiple sclerosis po

204 s pain; and the potential role of surgery as first-line therapy in advanced chronic pancreatitis.

205 irinotecan (FOLFIRI) regimen is superior as first-line therapy in advanced or metastatic KRAS wild-t

206 port the use of noninvasive ventilation as a first-line therapy in appropriately selected critically

207 D-1 inhibitors supports using this option as first-line therapy in circumstances where rapid response

208 Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndro

209 stated that they prescribe beta-blockers as first-line therapy in order to remain compliant with gui

210 The administration of nab-PC as first-line therapy in patients with advanced NSCLC was e

211 aphy (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgk

212 irolimus to letrozole did not improve PFS as first-line therapy in patients with AI-naive advanced br

213 dity and mortality, and should be considered first-line therapy in patients with chronic lower extrem

214 em cell transplantation (autoSCT) as part of first-line therapy in patients with chronic lymphocytic

215 Although cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance rema

216 inase inhibitors (TKIs) are being offered as first-line therapy in patients with EGFR activating muta

217 S and ORR over standard-of-care sunitinib as first-line therapy in patients with intermediate- or poo

218 efficacy over interferon alfa (IFN-alpha) as first-line therapy in patients with metastatic renal cel

219 ated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC.

220 For first-line therapy in patients with performance status o

221 Thrombolytic therapy should be considered first-line therapy in pregnant patients with prosthetic

222 in the management of urethral strictures as first-line therapy in selected patients.

223 orting the use of vasopressin analogs as the first-line therapy in the ICU setting with knowledge of

224 Crizotinib, a first-line therapy in the treatment of advanced non-smal

225 Although FOLFIRI was an acceptable first-line therapy in the treatment of AGC with a better

226 isceral leishmaniasis (VL), is currently the first-line therapy in the VL elimination program of the

227 mab plus chemotherapy versus chemotherapy as first-line therapy in Western (n = 923) and Chinese (n =

228 nosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%)

229 se these dietary treatments, perhaps even as first-line therapy, including infantile spasms, myocloni

230 Time to relapse after first-line therapy is a predictor of response to seconda

231 rst line therapy, widespread use of PI-based first-line therapy is not warranted at this time, due to

232 Resistance of HIV to first-line therapy is predictable at 12 months when eval

233 d patients at high risk for poor outcomes to first-line therapy (m7-Follicular Lymphoma International

234 how that the population-wide use of multiple first-line therapies (MFT) against malaria yields a bett

235 cifically focusing on a strategy of multiple first-line therapies (MFT), and comparing it with strate

236 ates are achieved using androgen blockade as first-line therapy, most men progress toward hormone-ref

237 ic drugs have failed; however, its role as a first-line therapy needs further investigation.

238 Dantrolene is the first line therapy of malignant hyperthermia.

239 years; it is currently in widespread use for first line therapy of mesothelioma and non-small cell lu

240 ollow-up studies, POEM may become one of the first-line therapies of achalasia in the next future.

241 ith a median progression-free interval after first-line therapy of 38 days were enrolled; 69 patients

242 t serves as the present standard of care for first-line therapy of advanced clear cell renal cell car

243 linifanib with carboplatin and paclitaxel as first-line therapy of advanced nonsquamous NSCLC.

244 s focused on 806 patients receiving adjuvant first-line therapy of carboplatin and paclitaxel with cu

245 men represents a highly active treatment for first-line therapy of follicular non-Hodgkin's lymphoma.

246 Peginterferon alfa has a place as first-line therapy of hepatitis B in patients who are ca

247 r to standard ATRA and chemotherapy (CHT) in first-line therapy of low- or intermediate-risk acute pr

248 to fluorouracil (FU) plus leucovorin (LV) in first-line therapy of metastatic colorectal cancer.

249 s benchmark end points for the CP regimen in first-line therapy of metastatic melanoma.

250 ) or lenalidomide-dexamethasone (59; 42%) as first-line therapy of multiple myeloma followed by repea

251 First-line therapy of severe aplastic anemia (SAA) with

252 ide-based regimens can be considered for the first-line therapy of WM and should take into account sp

253 at high doses, beta-adrenergic blockers, the first-line therapy, often are ineffective; the same is t

254 where efficacy may be further enhanced as in first-line therapy or after cytoreductive therapy.

255 er, clinicians may recommend either standard first-line therapy or, for selected patients, endocrine

256 with nonsteroidal anti-inflammatory drugs as first-line therapy, or tramadol or duloxetine as second-

257 adverse prognostic factor for survival after first-line therapy (P < .0001), independently of the int

258 For first-line therapy, patients in the EDP-mitotane group h

259 After 16 weeks of first-line therapy, patients with stable or responding t

260 emotherapy include the degree of response to first-line therapy, performance status, the likelihood o

261 alcium channel blocker ingestion (1D); 2) as first-line therapies (prioritized based on desired effec

262 idation therapy with biological agents after first-line therapy provide a framework for the developme

263 Using bevacizumab in first-line therapy provided an additional 0.10 QALYs (0.

264 alysis found that etanercept-methotrexate as first-line therapy provided marginally more QALYs but ac

265 Despite improvements in first-line therapies, published results on the treatment

266 Patients (N = 86; 69 as first-line therapy) received cisplatin (n = 43) or carbo

267 ter arterial chemoembolization (TACE) is the first-line therapy recommended for patients with interme

268 tients who have mRCC refractory to one prior first-line therapy regimen is underway.

269 VEGF-inhibiting agents should be confined to first-line therapy, second-line therapy or both.

270 logue with a high barrier to resistance as a first-line therapy, such as entecavir or tenofovir, prov

271 ho progressed within 9 months after start of first-line therapy, then in all patients with adenocarci

272 Given the high frequency of failure of first-line therapies, there is an urgent need for second

273 utcome of patients treated with dasatinib as first-line therapy to identify patients who are more lik

274 CLRT-SLT may be offered as first-line therapy to patients with HCC and well-compens

275 gh more than 80% of these women benefit from first-line therapy, tumour recurrence occurs in almost a

276 azole in Iran is low and this drug should be first line therapy, unless drug susceptibility testing s

277 were refractory or resistant (< 3 months) to first-line therapy warrants further development.

278 he ORR in 43 patients who never responded to first-line therapy was 16.3% (95% CI, 6.8% to 30.7%).

279 First-line therapy was four or more cycles of platinum d

280 Moreover, lack of response to first-line therapy was the most dominant prognostic fact

281 tance implications of PI- versus NNRTI-based first line therapy, widespread use of PI-based first-lin

282 as the treatment horizon broadens, choosing first-line therapies will become more complicated, with

283 ents with NSCLC who are being considered for first-line therapy with an EGFR TKI (patients who have n

284 compared with other antihypertensive agents, first-line therapy with beta-blockers was associated wit

285 nts with disease progression during or after first-line therapy with bevacizumab, oxaliplatin, and a

286 lts suggest that in elderly CLL patients the first-line therapy with fludarabine alone does not resul

287 1 were analyzed in the CLL8 study evaluating first-line therapy with fludarabine and cyclophosphamide

288 r CLL patients older than 65 years comparing first-line therapy with fludarabine with chlorambucil.

289 First-line therapy with gefitinib administered in a geno

290 o experience treatment failure with standard first-line therapy with gemcitabine or for whom gemcitab

291 atients who experienced treatment failure on first-line therapy with gemcitabine.

292 experienced treatment failure with standard first-line therapy with gemcitabine.

293 In this study, first-line therapy with pembrolizumab in patients with a

294 ee survival was significantly improved after first-line therapy with pertuzumab, trastuzumab, and doc

295 advanced hepatocellular carcinoma following first-line therapy with sorafenib.

296 ion who had locally defined viral failure on first-line therapy with tenofovir plus a cytosine analog

297 addition of either pertuzumab or placebo to first-line therapy with trastuzumab and docetaxel for pa

298 y cholangitis have an inadequate response to first-line therapy with ursodeoxycholic acid.

299 tane than with streptozocin plus mitotane as first-line therapy, with similar rates of toxic events,

300 ab (RTX) to high-dose dexamethasone (DEX) as first-line therapy yields higher sustained response rate